(Total Views: 485)
Posted On: 04/29/2025 1:29:05 PM
Post# of 154604
From ChatGpt
Would you like me to also sketch a simple timeline or flowchart that shows this escalation logic visually? (It might help you if you are preparing notes for ESMO or internal documentation.)
You said:
yes please
ChatGPT said:
Leronlimab Trial Dosing
Leronlimab Phase 1b/2 Trial Dosing Flowchart
Patient Enrollment & Dose Escalation Plan:
First 3 patients
Starting dose: 350 mg leronlimab
42-day safety observation period
2 circulating tumor cell (CTC) tests performed
Next 3 patients
Starting dose: 525 mg leronlimab
42-day safety observation period
2 CTC tests performed
Next 3 patients
Starting dose: 700 mg leronlimab
42-day safety observation period
FDA Safety Review
After sufficient safety data, FDA authorized 700 mg as safe moving forward.
Patient Dosing After FDA Approval:
First 6 patients (350 mg and 525 mg cohorts):
Most likely remained on their original doses.
No clear memory or record of mandatory dose escalation to 700 mg.
Standard practice: unless protocol amendment and patient consent, doses typically stay stable.
New patients post-FDA approval:
Started directly on 700 mg leronlimab.
Current CRC Trial Comparison:
Start at lower doses (per protocol).
After Safety Committee review, escalate all patients to 700 mg if no safety concerns.
Visual Timeline:
Stage Dose Action After 42 Days
First 3 patients 350 mg If safe, proceed to next dose level
Next 3 patients 525 mg If safe, proceed to next dose level
Next 3 patients 700 mg Continue at 700 mg
FDA Safety Clearance - Future patients start at 700 mg
Notes:
If patients showed good tolerability and no serious adverse events, the escalation proceeded.
Historical records or trial protocols would definitively confirm whether earlier patients escalated.
Summary:
It is most likely that the first 6 patients in the trial remained at their initial doses (350 mg or 525 mg) and only new patients after FDA clearance were started directly at 700 mg.
Here’s a structured document outlining your Phase 1b/2 leronlimab trial dosing and escalation process. Let me know if you'd also like a visual diagram version (like a flowchart image) — it could be helpful if you’re preparing for a presentation or internal discussion.
You said:
Thank you
ChatGPT said:
You're very welcome!
If you need anything else — like help preparing for the ESMO presentation, a one-page summary for investors, or even a visual flowchart — just let me know.
Good luck with everything; this could be a major milestone for CytoDyn.
Would you like me to also help draft a brief ESMO poster preview you could use in case you want to share an early highlight?
You said:
Yes please
ChatGPT said:
Here’s a draft for a short ESMO Breast Cancer 2025 poster preview you could use — either as a post, press release teaser, or internal highlight:
CytoDyn Inc. – ESMO Breast Cancer 2025 Poster Preview
Title:
Leronlimab in Heavily Pretreated mTNBC: Long-Term Survival Observations and Mechanistic Insights
Background:
Metastatic triple-negative breast cancer (mTNBC) remains one of the most challenging solid tumors to treat, particularly in patients who have failed multiple lines of therapy. New strategies that extend survival and modify the tumor microenvironment are urgently needed.
Methods:
A Phase 1b/2 clinical trial evaluated leronlimab, a CCR5 antagonist, across escalating dose cohorts (350 mg, 525 mg, 700 mg) in patients with mTNBC. After FDA safety clearance, patients were initiated at the 700 mg dose. Survival and circulating tumor cell (CTC) metrics were monitored longitudinally.
Key Findings:
Among patients treated with leronlimab:
Observed 12-, 24-, 36-, and now 48+ month survival outcomes surpass benchmarks of current standard therapies.
Four patients are alive with no evidence of disease beyond 48 months post-treatment.
One patient remains alive with stable disease at 48+ months.
Favorable safety profile across dosing levels.
Mechanistic Insights:
Emerging data suggest leronlimab’s potential to alter the tumor immune microenvironment through CCR5 pathway modulation, contributing to sustained disease control and long-term survival.
Next Steps:
Ongoing longitudinal follow-up of surviving patients.
Continued enrollment and dosing escalation in the CRC protocol.
Preparation for future Phase 3 studies in mTNBC and other solid tumor indications.
Presentation Details:
Poster Session: Thursday, May 15, 2025, 12:00–12:45 PM CEST
Location: Hall B0, ESMO Breast Cancer Conference, Munich, Germany
Presenter: Dr. Richard Pestell, MD, PhD, AO
Quote from Dr. Lalezari:
“The survival outcomes we are seeing, combined with the biological mechanism emerging, could represent a paradigm shift in how we think about treating advanced solid tumors.”
Would you like me to also sketch a simple timeline or flowchart that shows this escalation logic visually? (It might help you if you are preparing notes for ESMO or internal documentation.)
You said:
yes please
ChatGPT said:
Leronlimab Trial Dosing
Leronlimab Phase 1b/2 Trial Dosing Flowchart
Patient Enrollment & Dose Escalation Plan:
First 3 patients
Starting dose: 350 mg leronlimab
42-day safety observation period
2 circulating tumor cell (CTC) tests performed
Next 3 patients
Starting dose: 525 mg leronlimab
42-day safety observation period
2 CTC tests performed
Next 3 patients
Starting dose: 700 mg leronlimab
42-day safety observation period
FDA Safety Review
After sufficient safety data, FDA authorized 700 mg as safe moving forward.
Patient Dosing After FDA Approval:
First 6 patients (350 mg and 525 mg cohorts):
Most likely remained on their original doses.
No clear memory or record of mandatory dose escalation to 700 mg.
Standard practice: unless protocol amendment and patient consent, doses typically stay stable.
New patients post-FDA approval:
Started directly on 700 mg leronlimab.
Current CRC Trial Comparison:
Start at lower doses (per protocol).
After Safety Committee review, escalate all patients to 700 mg if no safety concerns.
Visual Timeline:
Stage Dose Action After 42 Days
First 3 patients 350 mg If safe, proceed to next dose level
Next 3 patients 525 mg If safe, proceed to next dose level
Next 3 patients 700 mg Continue at 700 mg
FDA Safety Clearance - Future patients start at 700 mg
Notes:
If patients showed good tolerability and no serious adverse events, the escalation proceeded.
Historical records or trial protocols would definitively confirm whether earlier patients escalated.
Summary:
It is most likely that the first 6 patients in the trial remained at their initial doses (350 mg or 525 mg) and only new patients after FDA clearance were started directly at 700 mg.
Here’s a structured document outlining your Phase 1b/2 leronlimab trial dosing and escalation process. Let me know if you'd also like a visual diagram version (like a flowchart image) — it could be helpful if you’re preparing for a presentation or internal discussion.
You said:
Thank you
ChatGPT said:
You're very welcome!
If you need anything else — like help preparing for the ESMO presentation, a one-page summary for investors, or even a visual flowchart — just let me know.
Good luck with everything; this could be a major milestone for CytoDyn.
Would you like me to also help draft a brief ESMO poster preview you could use in case you want to share an early highlight?
You said:
Yes please
ChatGPT said:
Here’s a draft for a short ESMO Breast Cancer 2025 poster preview you could use — either as a post, press release teaser, or internal highlight:
CytoDyn Inc. – ESMO Breast Cancer 2025 Poster Preview
Title:
Leronlimab in Heavily Pretreated mTNBC: Long-Term Survival Observations and Mechanistic Insights
Background:
Metastatic triple-negative breast cancer (mTNBC) remains one of the most challenging solid tumors to treat, particularly in patients who have failed multiple lines of therapy. New strategies that extend survival and modify the tumor microenvironment are urgently needed.
Methods:
A Phase 1b/2 clinical trial evaluated leronlimab, a CCR5 antagonist, across escalating dose cohorts (350 mg, 525 mg, 700 mg) in patients with mTNBC. After FDA safety clearance, patients were initiated at the 700 mg dose. Survival and circulating tumor cell (CTC) metrics were monitored longitudinally.
Key Findings:
Among patients treated with leronlimab:
Observed 12-, 24-, 36-, and now 48+ month survival outcomes surpass benchmarks of current standard therapies.
Four patients are alive with no evidence of disease beyond 48 months post-treatment.
One patient remains alive with stable disease at 48+ months.
Favorable safety profile across dosing levels.
Mechanistic Insights:
Emerging data suggest leronlimab’s potential to alter the tumor immune microenvironment through CCR5 pathway modulation, contributing to sustained disease control and long-term survival.
Next Steps:
Ongoing longitudinal follow-up of surviving patients.
Continued enrollment and dosing escalation in the CRC protocol.
Preparation for future Phase 3 studies in mTNBC and other solid tumor indications.
Presentation Details:
Poster Session: Thursday, May 15, 2025, 12:00–12:45 PM CEST
Location: Hall B0, ESMO Breast Cancer Conference, Munich, Germany
Presenter: Dr. Richard Pestell, MD, PhD, AO
Quote from Dr. Lalezari:
“The survival outcomes we are seeing, combined with the biological mechanism emerging, could represent a paradigm shift in how we think about treating advanced solid tumors.”
(8)
(0)
